Glpg-0492 clinical trials
Also written GLPG0492.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses glpg-0492 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GLPG0492
- 3
Studies by the year they started
3 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses glpg-0492 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- First-in-Human Single Ascending Dose of GLPG0492CompletedPhase 1Galapagos NVNCT01130818Written as GLPG0492
- GLPG0492 PharmacodynamicsCompletedPhase 1Galapagos NVNCT01538420Written as GLPG0492
- Multiple Ascending Dose Study of GLPG0492 in Healthy SubjectsCompletedPhase 1Galapagos NVNCT01397370Written as GLPG0492
Codes
What other systems call glpg-0492 · ClinicalTrials.gg INT006201
- Wikidata Q27270808GLPG-0492One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q27270808 | GLPG-0492 | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.